

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:<https://orca.cardiff.ac.uk/id/eprint/149252/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Pattinson, R. , Trialonis-Suthakharan, N., Austin, J., Augustin, M. and Bundy, C. 2022. POSB369 development of the patient-reported impact of dermatological diseases (PRIDD) measure. Value in Health 25 (1) , S232. 10.1016/j.jval.2021.11.1136

Publishers page: <http://dx.doi.org/10.1016/j.jval.2021.11.1136>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Development of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure

Rachael Pattinson¹, Nirohshah Trialonis-Suthakharan², Jennifer Austin³, Matthias Augustin², Christine Bundy¹

¹Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Germany. ²School of Healthcare Sciences, Cardiff University, UK. ³International Alliance of Dermatology Patient Organizations, Ottawa, Canada.

OBJECTIVES: Dermatological conditions are the fourth most common health condition worldwide and carry a physical, psychological and social burden for patients. The existing burden metrics in dermatology (e.g. patient-reported outcome measures [PROMs]) arguably underestimate the breadth of the impact of dermatological conditions on patients' lives. The Global Research on the Impact of Dermatological Diseases (GRIDD) project is developing a new measure (Patient-Reported Impact of Dermatological Diseases - PRIDD) to better understand the true impact. GRIDD is the first global patient-initiated and -led impact research study in dermatology.

METHODS: This mixed methods study meets the gold-standard COSMIN (consensus-based standards for the selection of health measurement instruments) criteria. Adults (≥18-years) with a dermatological condition were recruited through the International Alliance of Dermatology Patient Organizations' global membership network. First, a COSMIN systematic review evaluated existing dermatology-specific (used across conditions) PROMs. Next, the qualitative interview study developed a conceptual framework of impact. Subsequently, a Delphi study elicited consensus on items to prioritise for inclusion in PRIDD. Currently, a cognitive interview study is evaluating the content validity, acceptability and feasibility of PRIDD. The final stage will be psychometric testing.

RESULTS: The systematic review found that none of the 36 identified PROMs met the criteria to be recommended for use. The interview study (n = 63; 29 dermatological conditions; 29 countries) established impact as a multifaceted concept involving physical, psychological, social, financial and daily functioning. The Delphi study (n = 1154; 90 dermatological conditions; 61 countries) reduced an initial item pool of 263 impacts to produce the first draft of PRIDD (33 items across five domains).

CONCLUSION: PRIDD addresses shortcomings in existing PROMS and greatly enhances patient perspectives in dermatology by providing quantifiable patient-impact data. It supports local, regional and international attempts to better position the dermatology community (patients, patient organizations, health-care professionals, researchers, industry).